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Abstract The neural networks that putatively modulate
aspects of normal emotional behavior have been implicated
in the pathophysiology of mood disorders by converging
evidence from neuroimaging, neuropathological and lesion
analysis studies. These networks involve the medial pre-
frontal cortex (MPFC) and closely related areas in the
medial and caudolateral orbital cortex (medial prefrontal
network), amygdala, hippocampus, and ventromedial parts
of the basal ganglia, where alterations in grey matter vol-
ume and neurophysiological activity are found in cases
with recurrent depressive episodes. Such ﬁndings hold
major implications for models of the neurocircuits that
underlie depression. In particular evidence from lesion
analysis studies suggests that the MPFC and related limbic
and striato-pallido-thalamic structures organize emotional
expression. The MPFC is part of a larger ‘‘default system’’
of cortical areas that include the dorsal PFC, mid- and
posterior cingulate cortex, anterior temporal cortex, and
entorhinal and parahippocampal cortex, which has been
implicated in self-referential functions. Dysfunction within
and between structures in this circuit may induce distur-
bances in emotional behavior and other cognitive aspects
of depressive syndromes in humans. Further, because the
MPFC and related limbic structures provide forebrain
modulation over visceral control structures in the hypo-
thalamus and brainstem, their dysfunction can account for
the disturbances in autonomic regulation and neuroendo-
crine responses that are associated with mood disorders.
This paper discusses these systems together with the neu-
rochemical systems that impinge on them and form the
basis for most pharmacological therapies.
The World Health Organization ranks major depressive
disorder (MDD) and bipolar disorder (BD) as the ﬁrst and
ﬁfth leading causes of years lived with disability (WHO
2001), respectively, yet almost nothing is known about
their pathogenesis. Because these conditions were not
associated with gross brain pathology or with clear animal
models for spontaneous, recurrent mood episodes, the
availability of tools allowing noninvasive assessment of
the human brain proved critical to elucidating their
neurobiology. The recent development of neuroimaging
technologies that permit in vivo characterization of the
anatomical, physiological and neurochemical correlates of
mood disorders thus has enabled signiﬁcant advances
toward illuminating the pathophysiology of these condi-
tions. Notably, the results of neuroimaging studies and the
post mortem studies that have been guided by neuro-
imaging results have given rise to neurocircuitry-based
models in which both functional and structural brain
pathology play roles in the development of mood disorders.
The symptomatology of the clinical syndrome shared by
MDD and BD, namely the major depressive episode,
implicates brain systems involved in the regulation of mood
and emotional expression, reward processing, attention,
motivation, stress responses, social cognition and neuro-
vegetative function (e.g., sleep, appetite, energy, libido).
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episodes (MDE) require persistence of either depressed
mood or loss of interest and pleasure, in association with at
least four of the following symptoms: inattention, fatigue,
self-depreciating or suicidal thoughts, and disturbances of
psychomotor activity, sleep, appetite and weight (APA
1994). Anxiety symptoms also are prominent during MDE,
and mood disorders commonly occur comorbidly with
anxiety disorders such as panic disorder, social phobia,
posttraumatic stress syndrome and obsessive–compulsive
disorder (Kessler et al. 2005). These comorbid syndromes
generally worsen or improve in tandem with the severity of
depressive symptoms. In BD episodes of depression occur
alternately with manic or hypomanic episodes, during
which the mood becomes euphoric and labile, the capacity
for deriving pleasure increases, behaviors aimed at deriving
pleasure increase, and energy, psychomotor activity, libido
and self esteem become elevated. The symptomatology for
mania thus implicates the same functional domains as those
that characterize MDE, but in a manner that is phenome-
nologically antithetical.
In this paper, we consider the neurobiological bases of
these clinical features by reviewing the abnormalities of
brain structure and function that have been discovered in
patients with mood disorders, and integrate these ﬁndings
with information obtained about the function of putatively
homologous brain systems in experimental animals. The
data acquired from depressed patients that are presented
below emphasize morphological, physiological and chemi-
cal data assessed via in vivo neuroimaging and post mortem
neuropathological techniques. The neuroanatomical infor-
mation contained within these studies are discussed by
considering the prominent neural connections between
implicated brain regions to construct circuit-based models
that suggest mechanisms by which dysfunction can precip-
itatethebehavioralsignsandsymptomsofaffectivedisease.
Weproposespeciﬁcallyaneuralmodelinwhichdysfunction
within the MPFC and in the circuits that connect the MPFC
to other cortical and limbic structures can account for the
disturbances of emotional behavior, cognitive performance,
neurotransmission, autonomic regulation and neuroendo-
crine responses that are associated with mood disorders.
Neurobiological correlates of mood disorders
Despite many psychological and biological theories
regarding the pathogenesis of mood disorders the etiologies
of primary MDD and BD remain unknown. The sponta-
neous and perseverative nature of MDE symptoms and
their responsiveness to antidepressant drugs suggest
abnormal brain processes that underlie and maintain these
conditions. Consistent with this expectation a variety of
neurophysiological, neuropathological, and neurochemical
abnormalities has been discovered in MDD and BD within
the neural systems that modulate emotional behavior. None
of these abnormalities has shown sufﬁcient sensitivity and
speciﬁcity to prove useful as a diagnostic test, however.
The variable presence and magnitude of such abnormali-
ties in mood disorders likely reﬂects the heterogeneity
encompassed within the MDD and BD syndromes with
respect to pathophysiology and etiology. So long as psychi-
atric nosology depends on syndrome-based classiﬁcations,
diagnoses for MDD will continue to encompass patients with
a wide range of conditions that appear qualitatively and
quantitatively distinct. This lack of precise and biologically
veriﬁable deﬁnition of illness presumably contributes to the
inconsistencies extant within the literature pertaining to
neurobiological abnormalities associated with MDD, the
high-placebo effect observed in antidepressant treatment
trials, and the plethora of psychotherapeutic and biological
treatment options that reportedly exert antidepressant effects
(Drevetsand Todd 2005).Ultimately,the discovery ofillness
subtypes that are associated with speciﬁc biomarkers is
expected to improve the effect size and reproducibility of
research ﬁndings and therapeutic approaches.
Twin and other family studies indicate that genetic fac-
tors contribute substantially to the liability for developing
MDD and BD, particularly in cases characterized by
recurrent illness and early age-at-onset (Sullivan et al.
2000; Drevets and Todd 2005). The extant data suggest that
the transmission of mood disorders involves complex
interactions between multiple genes, each exerting rela-
tively small effects on vulnerability. Several single
nucleotide polymorphisms have been associated with
increased risk for developing depression, although few of
these ﬁndings are replicated. If conﬁrmed in additional
studies, these genetic markers would implicate neurotro-
phic, glutamatergic, cholinergic, serotonergic systems and
intracellular signaling pathways in the pathogenesis of
depression (Detera-Wadleigh and McMahon 2004). The
genetic data also support a role for acquired factors in dis-
ease expression (Sullivan et al. 2000). For example, a gene–
environmentinteractionwasdescribed inwhich afunctional
polymorphism in the serotonin transporter promoter region
increased the risk for developing MDE speciﬁcally within
the context of stress (Caspi et al. 2003).
Stressful events are thought to constitute ‘‘acquired
factors’’ that interact with genetic susceptibility in the
development of mood disorders, although once the illness
has been instantiated the potential links between stressors
and subsequent MDE become progressively less evident
(Drevets and Todd 2005). Early in the course of illness,
MDE commonly appear to follow severe, stressful life
events, whereas patients with recurrent MDD or BD
commonly report that their pattern of depressive symptoms
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123is unexplained by stressful life situations. Nevertheless,
even within the context of chronic depression, stressful life
events can severely and persistently worsen both the
severity of the current MDE and the course of illness with
respect to lowering the mood baseline to which patients
return between episodes (many patients with MDD and BD
develop progressive worsening of illness with failure to
return to the premorbid level of mood and function). This
downward trajectory is intensiﬁed by the problem that the
psychosocial impairment associated with MDE often
precipitates additional stressful events, such as job loss,
scholastic failure and marital conﬂict or separation.
A variety of physiological and medical stressors also
increase the risk for developing MDE. Notably the life-
event most clearly associated with the development of
depression and mania is the cessation of pregnancy, as the
post-partum period constitutes the epoch of greatest risk for
developing MDD or BD (Drevets and Todd 2005). Some
neurological disorders, medical conditions and pharmaco-
logical substances also increase the risk for developing
MDE, providing clues about the neurobiological systems in
which dysfunction may induce depressive symptoms. For
example, Parkinson’s disease (PD) is associated with a two-
to fourfold increase in the risk for developing MDE relative
to other similarly disabling conditions. In about one-half of
cases, the MDE onset precedes the onset of motor mani-
festations in PD (Santamaria et al. 1986). These ﬁndings led
to hypotheses that degeneration of dopaminergic and/or
serotonergic projections in PD impairs neural processes
underlying reward processing and mood modulation,
yielding depressive, anhedonic and anxiety symptoms.
Other medical diseases that increase the risk for
depression or mania include endocrine disturbances (e.g.,
Cushing’s syndrome), degenerative basal ganglia disorders
(e.g., Huntington’s or Wilson’s Diseases), temporal lobe
epilepsy, and structural lesions (tumors, infarcts, injury)
involving the striatum, frontal lobe or mesiotemporal cor-
tex (Drevets and Todd 2005). Pharmacologic agents that
may precipitate MDE include drugs which induce endo-
crine or neurochemical changes similar to those found in
primary mood disorders. For example, administration of
corticosteroids (e.g., prednisone) or monoamine depleting
agents (e.g., reserpine) result in neurochemical changes
that resemble, respectively, the hypercortisolemia and
reduced monoamineregic neurotransmitter function evident
in MDD, and also can induce MDE in susceptible indi-
viduals (Drevets and Todd 2005).
Neural circuits affected by mood disorders
Evidence from neuroimaging, neuropathological, and lesion
analysis studies implicates brain networks that normally
regulate the evaluative, expressive and experiential aspects
of emotional behavior in the pathophysiology of mood
disorders (Phillips et al. 2003). These circuits include the
limbic-cortical-striatal-pallidal-thalamic circuits (LCSPT),
formed by connections between the orbital and medial
prefrontal cortex (OMPFC), amygdala, hippocampal
subiculum, ventromedial striatum, mediodorsal and midline
thalamic nuclei and ventral pallidum (Ongu ¨r et al. 2003).
The LCSPT circuits initially were related to emotional
behavior on the basis of their anatomical connectivity with
visceral control structures that mediate emotional expres-
sion, such as the hypothalamus and periaqueductal gray
(PAG) (Nauta and Domesick 1984). They initially were
implicated in the pathophysiology of depression by the
observations that degenerative basal ganglia diseases and
lesions of the striatum and orbital cortex increased the risk
for developing MDE (Folstein et al. 1985). Because these
conditions affect synaptic transmission through the LCSPT
circuitry in diverse ways, it appears that dysfunction that
alters transmission through these circuits in various ways
can produce the pathological emotional symptoms encom-
passed by the MDE criteria (Drevets et al. 2004).
In addition to the LCSPT itself, neuroanatomical exper-
iments in monkeys have shown that the orbital and medial
prefrontal cortex is associated with two extended cortical
circuits. One of these, which is mainly related to the central
and lateral orbital areas (‘‘the orbital prefrontal network’’),
includes sensory association areas such as visual associated
areas in the inferior temporal cortex and somatic-sensory
associated areas in the insula and frontal operculum, as well
as olfactory and taste cortex (Ongu ¨r and Price 2000; Saleem
et al. 2008). In addition to sensory integration, this system
codes for affective characteristics of stimuli such as reward,
aversion, and relative value. The other extended cortical
system, which is primarily connected to the medial
prefrontal cortex and a small region in the caudolateral
orbital cortex (the ‘‘medial prefrontal network’’) includes
the dorsomedial/ dorsal anterolateral prefrontal cortex
(e.g.,BA9),themid-andposteriorcingulatecortex,aregion
in the anterior superior temporal gyrus and sulcus, and the
entorhinal and posterior parahippocampal cortex (Kondo
et al. 2005; Saleem et al. 2008). This system does not
have substantial sensory connections, but has prominent
connections with limbic structures and visceral control
structures (hypothalamus and periaqueductal gray) (Ongu ¨r
and Price 2000). This is the visceromotor system that is
particularly involved in introspective functions such as
mood and emotion, and visceral reactions to emotional
stimuli. It closely resembles the ‘‘default system’’ that has
been deﬁned in human functional imaging studies as a sys-
tem of areas that become deactivated from a resting
‘‘default’’ condition in most tasks that involve external
attention to objects or events outside the individual (e.g.,
Gusnard et al. 2001; Fox et al. 2005). Compatible with this
Brain Struct Funct (2008) 213:93–118 95
123hypothesis, pharmacological, neurosurgical, and deep brain
stimulation treatments for mood disorders appear to sup-
press pathological activity within the second visceromotor
network structures such as the subgenual anterior cingulate
cortex (sgACC), amygdala and ventral striatum (Drevets
et al. 2002a; Mayberg et al. 2005; Drevets and Price 2005;
Van Laere et al. 2006).
The extended visceromotor network also has been impli-
cated by neuroimaging studies of pathological anxiety
syndromesthatoccurcomorbidlywithMDDandBD(Charney
and Drevets 2002). Although combinations of depressive
and anxiety syndromes are classiﬁed by the current diag-
nostic nomenclature as a mood disorder plus a comorbid
anxiety disorder, researchers expect that they reﬂect dys-
function from a single etiology, which alters emotion
regulationwithinthe visceromotornetwork.Consistentwith
this expectation, antidepressant drugs are the ﬁrst-line
treatments for both depressive and anxiety disorders.
Brain structural abnormalities in mood disorders
Patients with mood disorders show abnormalities of mor-
phology or morphometry in many visceromotor network
structures (Drevets and Price 2005). The extent or preva-
lence of these abnormalities depends partly on clinical
characteristics such as age-at illness-onset, capacity for
developing mania or psychosis, and evidence for familial
aggregation of illness. For example, elderly MDD subjects
with late-onset depression show an increased prevalence of
neuroimaging correlates of cerebrovascular disease, rela-
tive both to age-matched, healthy controls and to elderly
depressives with an early age-at depression-onset (Drevets
et al. 2004). Similarly, MDD and BD cases who have either
psychosis (delusions and/or hallucinations) or a late-life
illness-onset show nonspeciﬁc signs of atrophy, such as
lateral ventricle enlargement that are absent in early-onset,
nonpsychotic MDD cases.
Nevertheless, early-onset, nonpsychotic MDD and BD
cases also consistently show volumetric abnormalities
that are localized to some PFC, cingulate and temporal
lobe structures (Table 1). The most prominent volumetric
abnormality reported to date has been a reduction in gray
matter in the left anterior cingulate cortex (ACC) ventral
to the corpus callosum genu (i.e., ‘‘subgenual’’) which is
evident in MDD and BD with evidence of familial
clustering or with psychotic features (Botteron et al.
2002; Coryell et al. 2005; Drevets et al. 1997; Hirayasu
et al. 1999). Preliminary data suggest this volumetric
reduction exists early in illness and in young adults at
high familial risk for MDD (Botteron et al. 2002; Hira-
yasu et al. 1999).
Gray matter volume also is reduced in the orbital (BA
11, 47) and ventrolateral PFC (VLPFC; BA 45, 47) in
MDD (Drevets and Price 2005) and BD (Lyoo et al. 2004)
Table 1 Neuroimaging and histopathological abnormalities evident in the visceromotor network (Ongu ¨r et al. 2003) in early-onset, recurrent
major depressive disorder and/or bipolar disorder
Brain region Gray matter volume Cell counts, cell markers Glucose metabolism, CBF
Dep versus Con Dep versus Con Dep versus Con Dep versus Rem
Dorsal medial/anterolateral PFC (BA9) ;; ; ;
Frontal polar C (BA 10) ;; ;
Subgenual anterior cingulate C ;; ; /;
a ;
Pregenual anterior cingulate C ;; ; ;
Orbital C/ventrolateral PFC ;; ; ;
Posterior cingulate ;; ;
Parahippocampal C ;; BD ;;
Amygdala ;/:
b ; MDD ;;
Ventromedial striatum ;; ;
Hippocampus ;; BD n.s. n.s.
Superior temporal G/temporopolar C ; ;
Medial thalamus ;;
a In the subgenual anterior cingulate cortex the apparent reduction in CBF and metabolism in PET images of depressed subjects is thought to be
accounted for by the reduction in tissue volume in the corresponding cortex, as after partial volume correction for the reduction in gray matter the
metabolism appears increased relative to controls
b The literature is in disagreement with respect to the amygdala volume in mood disorders. In MDD, the volume appears reduced in cases whose
MDE show a chronic or intermit course
C cortex, Dep versus Con unmedicated depressives versus healthy controls, Dep versus Rem unmedicated depressives versus themselves in either
the medicated or unmedicated remitted phases, G gyrus, n.s. differences generally not signiﬁcant, PFC prefrontal cortex
Empty cells indicate insufﬁcient data. Modiﬁed from (Drevets 2007)
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123the frontal polar/dorsal anterolateral PFC (BA 9, 10) in
MDD (Drevets et al. 2004), and the posterior cingulate
cortex and superior temporal gyrus in BD (Nugent et al.
2006). In BD the peak difference in gray matter loss in the
lateral orbital cortex was found in the sulcal BA47 cortex
(Nugent et al. 2006), a region that appears to correspond to
an area which Ongu ¨r et al. proposed is related to the MPFC
as part of the medial prefrontal network (Figs. 1, 2). In
addition, white matter is decreased in the genu of the
corpus callosum in both adults with MDD or BD and their
high-risk child and adolescent offspring (particularly in
females), and in the splenium of the corpus callosum in
adults with MDD or BD.
Some studies also reported reductions in hippocampal
volume in MDD, ranging in magnitude from 8 to 19%,
although other studies did not replicate these differences
(Drevets et al. 2004). The discrepant results across studies
may reﬂect clinical heterogeneity as one study reported that
reduced hippocampal volume was limited to depressed
women who suffered early-life trauma, Vythilingam et al.
(2002) and others reported that hippocampal volume cor-
related inversely with time spent depressed (e.g., Sheline
Anterior temporal C
Amygdala
Parahippocampal C
Retrosplenial C
Cingulate C
Subiculum
Ventro-
medial
Striatum
Thalamus
PV, MD
PAG
Hypothalamus
Fig. 1 Regions and anatomical projections that form the extended
visceromotor network. The cytoarchitectonic subdivisions of the
human orbital (upper left) and medial prefrontal cortical surfaces
(lower left) are distinguished here as being predominantly in the
visceromotor (pink) or sensory (green) networks described in (Ongu ¨r
and Price 2000). These portions of the ﬁgure are modiﬁed from Ongu ¨r
et al. (2003), with the lighter shade of pink reﬂecting more recent
work regarding the portions of the medial wall that share the
connectional features of the visceromotor network. The area shown in
blue, the sulcal portion of BA 47 [47 s; which corresponds to orbital
portion of Walker area 12 (i.e., 12o) of the monkey; see Fig. 2],
shares features of both the visceromotor and sensory networks. This
region and the anterior (agranular) insula (Ia) continue into the lateral
cortical wall, so are better viewed in the coronal sections shown in
Ongu ¨r et al. 2003). The major structures that receive efferent
projections from the visceromotor component of the OMPFC are
indicated on the right panel over the brain diagram. These include the
posterior cingulate cortex, the anterior temporal cortex, and the
entorhinal and parahippocampal cortex, all of which are implicated in
the ‘‘default system’’ (Hsu and Price 2007; Kondo et al. 2003, 2005;
Price 2007; Saleem et al. 2007, 2008). C cortex, MD mediodorsal
nucleus of the thalamus, PAG periaqueductal gray; PV periventricular
nucleus of the thalamus
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volumetric reductions in the anterior subiculum/ventral
CA1 region appeared speciﬁc to BD.
Elucidating the effect of such clinical variables may also
prove helpful in resolving disagreements in the literature
regarding the existence of morphometric abnormalities in
the amygdala and striatum. In the amygdala, the volume
has been reported to be increased in some studies but
decreased in others in depressives relative to controls
(Drevets et al. 2004). In the striatum Husain et al. (1991)
reported that the putamen was smaller in depressives than
controls, and Krishnan et al. (1992) found a smaller cau-
date nucleus volume in depressives than controls. In a
sample limited to elderly depressives, Krishnan et al.
(1993) also reported smaller putamen and caudate volumes
relative to controls. These ﬁndings were consistent with the
post mortem study of Baumann et al. (1999), which found
that caudate and accumbens area volumes were markedly
decreased in both MDD and BD samples relative to control
samples. Nevertheless, other studies found no signiﬁcant
Fig. 2 Architectonic maps of the orbital (upper and right-center
panels) and medial prefrontal cortical surfaces (left-center panel)o f
the macaque brain, modiﬁed from Carmichael and Price (1994). The
upper panel shows the areas hypothesized to form the ‘‘sensory’’
network of the orbital cortex based upon their afferent connections
with various sensory domains, which are indicated next to each set of
regions. This sensory network projects into the ‘‘visceromotor’’
network (middle panel). This latter network shares extensive,
reciprocal connections with the amygdala, periaqueductal gray and
hypothalamus (shown in coronal sections at the lower right, center
and left, respectively), areas which play major roles in organizing or
mediating the endocrine, autonomic, and behavioral aspects of
emotional behavior. The speciﬁc cytoarchitectonic areas of the
visceromotor component of the orbitomedial PFC are color coded
according to the speciﬁc nuclei of the amygdala and hypothalamus or
the column of the PAG to which they predominantly project
(Carmichael and Price 1995; Ongu ¨r and Price 1998; Floyd et al.
2000, 2001). Bvl ventrolateral part of the basal nucleus of the
amygdala, Ce central nucleus of the amygdala, DH dorsal hypotha-
lamic area, LH lateral hypothalamic area, MH medial hypothalamic
area; dlPAG, lPAG, vlPAG dorsolateral, lateral, and ventrolateral
columns of the PAG, respectively
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123difference in stiatal or pallidal volumes between younger
MDD subjects and controls (Drevets et al. 2004).
Conventional antidepressant drug treatment and symp-
tom remission do not appear to alter the reductions in gray
matter volume in the sgACC (Drevets et al. 1997), but may
arrest further gray matter decrements in the hippocampus
(Sheline et al. 2003). However, chronic lithium treatment,
which exerts robust neurotrophic effects in animal models,
has been associated with increasing gray matter volume
toward normal in treatment responders in the sgACC and
other PFC areas (Moore et al. 2008).
Finally, consistent with evidence that the hypothalamic-
pituitary-adrenal axis function is elevated in some mood-
disordered subgroups, the pituitary and adrenal glands are
reportedly enlarged in MDD. For example Krishnan et al.
(1991) showed that MRI-based measures of cross-sectional
area and volume of the pituitary were increased (by 34 and
41%, respectively) in depressives versus controls. This
observation is consistent with evidence that the adrenal
gland is also abnormally enlarged in MDD (reviewed in
Drevets et al. 2004), putatively due to chronically elevated
stimulation of the adrenal cortex by ACTH.
Neurophysiological imaging abnormalities in mood
disorders
Many of the regions where structural abnormalities are
apparent in mood disorders also contain abnormalities of
cerebral blood ﬂow (CBF) and glucose metabolism
(Table 1; Fig. 3). In most of these structures, and particu-
larly those which form the extended visceromotor network
(see above), the basal activity appears increased in the
depressed phase relative to the remitted phase of MDD.
This pattern of differences has been demonstrated by lon-
gitudinal studies of depressed patients imaged before
versus after treatment (e.g., Drevets et al. 2002a), or of
remitted patients scanned before versus during depressive
relapse (e.g., Neumeister et al. 2004).
Nevertheless,thereductioningraymattervolumeinsome
structuresissufﬁcientlyprominenttoproducepartialvolume
effects in functional brain images due to their relatively low
spatial resolution, yielding complex relationships between
physiological measures and depression severity. For exam-
ple, relative to controls, depressed MDD and BD subjects
show metabolic activity that appears reduced in the sgACC
(Drevetset al. 1997). However, whenthisvolumetric deﬁcit
istakeninto accountby correcting the metabolicdata for the
partial volume averaging effect associated with the corre-
sponding gray matter reduction (which have ranged in
magnitudefromabout20to50%across studiesofMDDand
BD), metabolism instead appears increased in the sgACC in
the unmedicated-depressed phase and normal in the medi-
cated-remitted phase (Drevets and Price 2005). The
volumetric reductions in the orbital cortex and VLPFC may
also contribute to the complexity of relationships observed
between metabolism and illness severity, as metabolism
appears elevated in depressed samples of mild-to-moderate
severity, but reduced in more severe, treatment refractory
cases (Drevets et al. 1992; Ketter et al. 2001).
Although the pattern of activity in the extended viscero-
motor network generally is one in which metabolism is
elevatedduringthedepressedrelativetotheremittedphases,
the relationship between physiological activity and symp-
tom severity differs in valence across some structures,
compatible with preclinical evidence that distinct MPFC
structuresareinvolvedinopponentprocesseswithrespectto
emotional behavior (Vidal-Gonzalez et al. 2006). Regions
where metabolism correlates positively with depression
severity include the amygdala, sgACC and ventromedial
frontal polar cortex (Drevets and Price 2005; Hasler et al.
2008). Metabolism and ﬂow decrease in these regions as a
common functional anatomical effect of both antidepressant
drug treatment and deep brain stimulation of the sgACC or
anterior capsule (Mayberg et al. 2005; Drevets et al. 2002a;
Van Laere et al. 2006; Mayberg et al. 1999), despite the
diverse mechanisms underlying these treatments. Con-
versely,inrecoveredMDDcaseswhoexperiencedepressive
relapse under experimental conditions involving serotonin
or catecholamine depletion, the metabolic activity increases
in these regions as the depressive symptoms return (Neu-
meisteret al.2004;Hasleretal.2008)althoughtheelevation
ofleftamygdalaactivityduringserotonindepletion-induced
relapse was limited to homozygotes for the long allele of the
serotonin transporter promoter region length polymorphism
(5HTT LPR) (Neumeister et al. 2006b).
In some regions abnormalities of physiological activity
appear speciﬁc to clinically deﬁned subtypes of mood
disorders. For example, in the amygdala, abnormal eleva-
tions of resting metabolism can be seen in depressed
samples categorized as having BD, familial pure depressive
disease (FPDD), MDD-melancholic type, or MDD which is
responsive to a night of total sleep deprivation (reviewed
in Drevets 2001). In such cases, amygdala metabolism
decreases toward normative levels during effective anti-
depressant treatment (Drevets et al. 2002a).
In contrast, a broader range of depressed subjects appears
to show abnormal hemodynamic responses in the amygdala
to emotional stimuli (as detailed below under the section,
Emotional Processing Bias). For example, the hemo-
dynamic responses of the left amygdala were smaller in
magnitude in depressed children (Thomas et al. 2001) and
adults (Drevets 2003) while viewing fearful faces, and
prolonged in duration in depressed adults while viewing sad
words (Siegle et al. 2002). In contrast, MDD cases showed
increased hemodynamic activity relative to controls in the
left amygdala in response to fearful (Sheline et al. 2001)
Brain Struct Funct (2008) 213:93–118 99
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masking technique (such that subjects were explicitly aware
only of having seen a face with a neutral expression). This
exaggerated left amygdala response was attenuated fol-
lowing successful antidepressant pharmacotherapy.
In the accumbens area, medial thalamus and posterior
cingulate cortex metabolism is abnormally elevated in the
depressed phase of MDD and BD (Drevets et al. 2002a,
2004).InfMRI studiestheregionalhemodynamicresponses
are attenuated in the ventral striatum in reward-processing
tasks, and in both the ventral striatum and the posterior
cingulateintasksinvolvingnegativefeedback(e.g.,Knutson
et al. 2007).
Neuropathological correlations in mood disorders
Most of the regions where MRI studies demonstrated
volumetric abnormalities in mood disorders also have been
shown to contain histopathological changes or gray matter
volumetric reductions in post mortem studies of MDD and
BD. For example, reductions of gray matter volume,
thickness or wet weight have been reported in the sub-
genual ACC, posterolateral orbital cortex, and ventral
striatum in MDD and/or BD subjects relative to controls
(Baumann et al. 1999; Bowen et al. 1989; Ongu ¨r et al.
1998; Rajkowska et al. 1999), and greater decrements in
volume following ﬁxation (implying a deﬁcit in the neu-
ropil) were demonstrated in the hippocampus in MDD
(Stockmeier et al. 2004). The histopathological correlates
of these abnormalities included reductions in glial cells
with no equivalent loss of neurons, reductions in synapses
or synaptic proteins, elevations in neuronal density, and
reductions in neuronal size in MDD and/or BD samples
(Rajkowska et al. 1999; Ongu ¨r et al. 1998; Cotter et al.
2001a, 2002; Eastwood and Harrison 2000, 2001; Uranova
et al. 2004). Reductions in glial cell counts and density,
Fig. 3 Areas of abnormally increased physiological activity in
familial MDD shown in images of unpaired t values, which were
computed using a statistical parametric mapping approach to compare
activity between depressives and controls (Drevets et al. 1992, 1997).
Upper left the positive t values in this sagittal section located 17 mm
left of midline (X =- 17) show areas were CBF is increased in
depressives versus controls in the amygdala and medial (MED) orbital
cortex (reproduced from Price et al. 1996). Upper right positive t
values in a sagittal section 41 mm left of midline (X =- 41) show
areas where CBF is increased in the depressives in the left
ventrolateral PFC (VLPFC), lateral orbitofrontal C, and anterior
insula (reproduced from Drevets et al. 2004). Lower right positive t
values in a coronal section located 19 mm posterior to the anterior
commissure (Y =- 19) shows an area where CBF is increased in the
depressives in the left medial thalamus (reproduced from Drevets and
Todd 2005). Lower left coronal (31 mm anterior to the anterior
commissure; Y = 31) and sagittal (3 mm left of midline; X =- 3)
sections showing negative voxel t values where glucose metabolism is
decreased in depressives relative to controls. The reduction in activity
in this prefrontal cortex (PFC) region located in the anterior cingulate
gyrus ventral to the genu of the corpus callosum (i.e., subgenual)
appeared to be accounted for by a corresponding reduction in cortex
volume (Table 1; reproduced from Drevets et al. 1997). Anterior or
left is to left
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MDD subjects versus controls in the pregenual ACC
(pgACC [BA24]) (Cotter et al. 2001a), the dorsal antero-
lateral PFC (BA9) (Cotter et al. 2002; Uranova et al. 2004)
and the amygdala (Bowley et al. 2002; Hamidi et al. 2004).
Finally, the mean size of neurons was reduced in the dorsal
anterolateral PFC (BA 9) in MDD subjects relative to
controls (Rajkowska et al. 1999), and the density of non-
pyramidal neurons was decreased in the ACC and
hippocampus in BD (Benes et al. 2001; Todtenkopf et al.
2005), and in the dorsal anterolateral PFC (BA9) of MDD
(Rajkowska et al. 2007). Reductions in synapses and syn-
aptic proteins were evident in BD subjects in the
hippocampal subiculum/ventral CA1 region (Eastwood and
Harrison 2000; Rosoklija et al. 2000), and the expression
of multiple genes involved in axonal growth/synaptic
function was reduced in the middle temporal cortex in
MDD subjects (Aston et al. 2005). Notably, in several of
these studies, the decreases were largely accounted for by
differences in the left hemisphere (e.g., Bowley et al. 2002;
Hamidi et al. 2004; Bowen et al. 1989; Ongu ¨r et al. 1998).
The glial type that speciﬁcally differed between MDD
and control samples in many of these studies was the oli-
godendrocyte (e.g., Uranova et al. 2004; Hamidi et al.
2004). Oligodendroglia are best characterized for their role
in myelination, and the reduction in oligodendrocytes may
conceivably arise secondary to an effect on myelin, either
through demyelination, abnormal development, or atrophy
in the number of myelinated axons. Notably, the myelin
basic protein concentration was found to be decreased in
the frontal polar cortex (BA 10) (Honer et al. 1999), and
the expression of genes related to oligodendrocyte function
(i.e., genes which encoded structural components of
myelin, enzymes involved in the synthesis of myelin
constituents or in the regulation of myelin formation,
transcription factors regulating other myelination-related
genes, or factors involved in oligodendrocyte differentia-
tion) was decreased in the middle temporal gyrus in MDD
subjects relative to controls (Aston et al. 2005). Compati-
ble with these data, the myelin staining was decreased in
the deep white matter of the dorsolateral PFC in MDD and
BD subjects (Regenold et al. 2007), and the white matter
volume of the genual and splenial portions of the corpus
callosum were abnormally reduced in MDD and BD (e.g.,
Brambilla et al. 2004). These regions of the corpus callo-
sum also were smaller in child and adolescent offspring of
women with MDD who had not yet developed a mood
disorder, relative to age-matched controls, suggesting that
the reduction in white matter in MDD reﬂects a develop-
mental defect that exists prior to illness onset (Martinez
et al. 2002). These observations are compatible with evi-
dence that the glial cell loss in mood disorders includes a
reduction in myelinating oligodendrocytes.
Another observation that supports this hypothesis is that
several reports of deﬁcits in glia in the cerebral cortex
depended upon laminar analysis, with the greatest effects in
layers III, V, and VI (Cotter et al. 2001a, 2002; Rajkowska
et al. 1999, 2001; Uranova et al. 2004; Vostrikov et al.
2007). The intracortical plexuses of myelinated ﬁbers
known as ‘‘Bands of Baillarger’’ are generally concentrated
in layers III and V. The size of these plexuses varies across
cortical areas, so if the oligodendrocytes related to these
plexuses were affected, different areas would be expected
to show greater or lesser deﬁcits. Layer VI in particular has
a relatively large component of myelinated ﬁbers running
between the gray and white matter.
Finally, satellite oligodendrocytes also were implicated
in the pathophysiology of mood disorders by electron
microscopic study of the PFC in BD which revealed
decreased nuclear size, clumping of chromatin and other
types of damage to satellite oligodendrocytes, including
indications of both apoptotic and necrotic degeneration
(Uranova et al. 2001; Vostrikov et al. 2007). Satellite
oligodendrocytes are immunohistochemically reactive for
glutamine synthetase, suggesting they function like astro-
cytes to take up synaptically released glutamate for
conversion to glutamine and cycling back into neurons
(D’Amelio et al. 1990).
In other brain regions, reductions in astroglia have been
reported by post mortem studies of mood disorders. In the
frontal cortex one study found that four forms of the
astrocytic product, glial ﬁbrillary acidic protein (GFAP),
were decreased in mood-disordered subjects relative to
controls, although it was not determined whether this
decrement reﬂected a reduction in the astrocyte density or
the GFAP expression (Johnston-Wilson et al. 2000).
However, another study which used immunohistochemical
staining for GFAP did not ﬁnd signiﬁcant differences in
cortical astrocytes between controls, and MDD or BD cases
(Webster et al. 2001). Other studies also did not ﬁnd
differences in GFAP between mood-disorder cases and
controls (reviewed in Cotter et al. 2001b).
Factors that may conceivably contribute to a loss of
oligodendroglia in mood disorders include the elevated
glucocorticoid secretion and glutamatergic transmission
evident during depression and mania. Glucocorticoids
affect both glia and neurons (Cheng and de Vellis 2000)
and elevated glucocorticoid concentrations and repeated
stress decrease the proliferation of oligodendrocyte pre-
cursors (Alonso 2000; Banasr and Duman 2007).
Moreover, oligodendrocytes express AMPA and kainate
type glutamate receptors, and are sensitive to excitotoxic
damage from excess glutamate (Dewar et al. 2003; Matute
et al. 1997; McDonald et al. 1998). The targeted nature of
the reductions in gray matter volume and glial cells to
speciﬁc areas of the limbic-cortical circuits that show
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is noteworthy given the evidence reviewed below that the
glucose metabolic signal is dominated by glutamatergic
transmission.
Correlations with rodent models of chronic and repeated
stress
The putative role of stress in precipitating MDE has pro-
moted the development of rodent stress models to facilitate
investigations of the neurobiological correlates of human
mood disorders. In regions that appear homologous to the
areas where gray matter reductions are evident in depressed
humans (i.e., medial PFC, hippocampus), repeated stress
results in dendritic atrophy and reductions in glial cell
counts or proliferation in rodents (Banasr and Duman 2007;
Czeh et al. 2005; McEwen and Magarinos 2001; Wellman
2001; Radley et al. 2008; Conrad et al. 1999). In the
basolateral amygdala (BLA), chronic, unpredictable stress
also produced dendritic atrophy, but chronic immobiliza-
tion stress instead increased dendritic branching (Banasr
and Duman 2007; Vyas et al. 2002, 2003), suggesting that
the effect of chronic immobilization stress on dendritic
remodeling is regionally speciﬁc (Conrad et al. 1999).
Dendritic atrophy presumably would be reﬂected by a
decrease the volume of the neuropil, which occupies most
of the gray matter volume. The similarities between the
histopathogical changes that accompany stress-induced
dendritic atrophy in rats and those found in humans suf-
fering from depression thus have led to hypotheses that
homologous processes underlie the reductions in gray
matter volume in hippocampal and PFC structures in MDD
and BD (McEwen and Magarinos 2001). In rats the stress-
induced dendritic atrophy in the medial PFC was associ-
ated with impaired modulation (i.e., extinction) of
behavioral responses to fear-conditioned stimuli (Izquierdo
et al. 2006). The observation that such changes inﬂuence
emotional expression are noteworthy in light of evidence
that volumetric reductions in humans with mood disorders
are associated with more severe and chronic pathological
mood episodes. Moreover, when rats were subjected to
repeated stress beyond 4 weeks, the dendritic atrophy
could be reversed by lithium administration (McEwen and
Magarinos 2001). The differential effects of these drugs on
dendritic atrophy in stressed rats thus resemble their effects
on sgACC volume in humans with BD (Moore et al. 2008;
Drevets et al. 1997; Drevets and Savitz 2008).
These dendritic reshaping processes depend on interac-
tions between the increased N-methyl-D-aspartate (NMDA)
receptor stimulation and glucocorticoid secretion associ-
ated with repeated stress (McEwen and Magarinos 2001).
Elevations of glutamate transmission and cortisol secretion
in mood disorders also may contribute to reductions in gray
matter volume and synaptic markers by inducing dendritic
atrophy in some brain structures, as the depressive subtypes
(e.g., BD, FPDD) who show regional reductions in gray
matter volume also show evidence of increased cortisol
secretion and glutamate transmission (Drevets et al.
2002b). Subjects with FPDD or familial BD also show
elevations of glucose metabolism, which largely reﬂects
glutamate transmission (see below), in the medial and
orbital PFC, amygdala, ventral striatum, and cingulate
cortex regions that show reductions in gray matter volume
and cellular elements. The ﬁndings that gray matter
reductions appear to occur speciﬁcally in regions that show
hypermetabolism during depression thus raise the possi-
bility that excitatory amino acid transmission plays a role
in the neuropathology of mood disorders. In many of the
regions where glucose metabolism is increased in the
depressed phase relative to the remitted phase, reductions
in cortex volume and/or histopathological changes have
been found in in vivo MRI studies and/or post mortem
studies of MDD and/or BD.
Neurochemical systems implicated in depression
Of the neurochemical systems that modulate neural trans-
mission within the visceromotor network, mood disorders
have been associated with abnormalities of serotonergic,
dopaminergic, noradrenergic, cholinergic, glutamatergic,
GABA-ergic, glucocorticoid and peptidergic [e.g., corti-
cotrophin releasing factor (CRF)] function. Agents that
impact monoamineregic neurotransmitter systems particu-
larly have received attention because most antidepressant
drugs exert their primary pharmacological actions through
these systems. However, the delayed onset of antidepres-
sant effects (generally lagging the initiation of treatment
by about 3 weeks) suggest that secondary mechanisms
involving changes in gene expression and/or synaptic
plasticity may underlie the therapeutic mechanisms of
these drugs. The neuropharmacological mechanisms
hypothesized to serve as ﬁnal common pathways for anti-
depressant responses include: (1) increases in the gene
expression of brain derived neurotrophic factor (BDNF)
and other neurotrophic/neuroprotective factors in the hip-
pocampus and PFC (Manji et al. 2001; Santarelli et al.
2003); (2) enhancement of postsynaptic serotonin type 1A
(5-HT1A) receptor function (Haddjeri et al. 1998; Chaput
et al. 1991); (3) attenuation of the sensitivity or transmis-
sion of NMDA-glutamatergic receptors (Krystal et al.
2002; Paul and Skolnick 2003).
Glutamatergic and GABA-ergic systems
The function of glutamate and c-amino-butyric acid
(GABA) appears altered in mood disorders. Early studies
102 Brain Struct Funct (2008) 213:93–118
123reported that GABA concentrations were abnormally
decreased in the plasma and cerebrospinal ﬂuid (CSF) in
MDD subjects (reviewed in Hasler et al. 2007). In contrast,
post mortem studies of the NMDA receptor complex in
suicide victims found evidence suggesting that glutama-
tergic transmission had been increased in the PFC
antemortem, and implicated disturbances in glutamate
metabolism, NMDA, and mGluR1,5 receptors in depres-
sion and suicide (Paul and Skolnick 2003). Moreover,
antidepressant and mood-stabilizing drugs which have
diverse primary pharmacological actions generally reduce
NMDA receptor sensitivity and/or transmission, and many
of these agents increase GABA levels or transmission
(Krystal et al. 2002; Paul and Skolnick 2003).
Elevated glutamatergic function is thought to support
the neurophysiological activation of visceromotor circuits
in depression. The anatomical projections between the
MPFC, striatum and amygdala implicated in mood disor-
ders are formed by predominantly excitatory projections in
rats and monkeys (Ongu ¨r et al. 2003; Ongu ¨r and Price
2000). Since cerebral glucose metabolism largely reﬂects
the energetic requirements associated with glutamatergic
transmission (Shulman et al. 2004), the elevated meta-
bolism evident in limbic-thalamo-cortical circuits in
depression implies that glutamatergic transmission is
increased in these circuits (Drevets et al. 1992; Swerdlow
and Koob 1987). During effective antidepressant drug or
electroconvulsive therapy, metabolic activity decreases in
these regions (Table 1; reviewed in Drevets et al. 2002a,
2004), compatible with evidence that these treatments
result in desensitization of NMDA receptors in the PFC
(Paul and Skolnick 2003). As described above, elevated
glutamatergic transmission within discrete anatomical cir-
cuits also may explain the targeted nature of gray matter
changes within mood disorders (e.g., affecting left more
than right sgACC) (McEwen and Magarinos 2001; Drevets
and Price 2005).
Magnetic resonance spectroscopic (MRS) studies of
MDD also demonstrate abnormalities of glutamate (mea-
sured together with cerebral glutamine as the combined
‘‘Glx’’ peak in the MRS spectra) and GABA concentra-
tions in MDD. These spectra reﬂect the combined
intracellular and extracellular pools of glutamate, gluta-
mine and GABA, but are dominated overwhelmingly by
the intracellular pools. Depressed MDD subjects show
abnormally reduced GABA levels in both, the dorsome-
dial/dorsal anterolateral PFC and the occipital cortex
(Sanacora et al. 1999; Hasler et al. 2007). The majority of
the GABA pool exists within GABAergic neurons, so the
reduction in GABA in the dorsal anterolateral PFC is
compatible with the report of reduced GABA-ergic neu-
rons in this region (BA9) in MDD (Rajkowska et al.
2007).
Depressed subjects also show abnormally reduced Glx
levels in the dorsomedial/dorsal anterolateral and ventro-
medial PFC regions where histopathological and
neurophysiological abnormalities are evident in depression
(Drevets and Price 2005). Since the Glx measure reﬂects
the intracellular glutamate and glutamine pools, the
abnormal reductions in Glx concentrations would be
compatible with the reductions in glial cells found post
mortem in the same regions in MDD, as glia play promi-
nent roles in glutamate–glutamine cycling.
Glucocorticoid system
The hypothalamic-pituitary-adrenocortical (HPA) axis
appears overactive in some patients with depression.
Severe depression is associated with hypersecretion of
cortisol, pituitary and adrenal gland enlargement, and
CSF–CRF levels that are increased to an extent that is
inappropriate to the plasma cortisol concentrations,
implying that both deﬁcits in negative feedback systems
and/or excessive central stimulation of the secretion of
CRF and/or other ACTH secretagogues exists in mood
disorders (Gold and Chrousos 2002; Drevets et al. 2004;
Swaab et al. 2005; Carroll et al. 2007). Depressed subjects
also show blunted ACTH responses to CRF in vivo, and
reduced CRF receptor density in the PFC and increased
corticotrophic cell size and mRNA levels in the pituitary
post mortem, indicating chronic activation of the HPA axis
(Gold and Chrousos 2002; Lopez et al. 1992; Swaab et al.
2005). Finally, some depressives show reduced sensitivity
to glucocorticoid ‘‘fast feedback’’ (Young et al. 1993) and/
or to dexamethasone negative feedback (Carroll et al.
1981), although these ﬁndings depend upon depressive
subtype, being most common in melancholic and psychotic
cases (Carroll et al. 2007). During successful treatment,
serum cortisol and CSF levels of CRF normalize, and
cortisol secretion becomes suppressible by dexamethasone
(Musselman and Nemeroff 1993). The chronic elevation of
cortisol secretion in some depressive subtypes is thought to
contribute to mitochondrial dysfunction, neuropathological
changes, elevated body temperature, premature osteopo-
rosis and aging, and other medical morbidity in individuals
suffering from mood disorders (McEwen and Magarinos
2001; Gold et al. 2002).
Serotonergic system
The central serotonin (5-HT) system has received particu-
lar attention in depression research because selective
serotonin reuptake inhibitors (SSRI) exert antidepressant
effects, and most other antidepressant drugs also increase
5-HT transmission. This effect of antidepressant drugs may
augment an endogenous elevation of serotonin release
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the enhanced 5-HT transmission that occurs in some brain
regions during stress in rodents (Cannon et al. 2007;B a r -
ton et al. 2008; Inoue et al. 1994). Enhancement of 5-HT
transmission in MDD also may compensate for the
abnormalities in density and sensitivity of some 5-HT
receptor subtypes evidenced by post mortem, neuroimag-
ing and pharmacological challenge studies of depression
(Stockmeier 2003). For example, postsynaptic 5-HT1A
receptor binding or mRNA expression is decreased in the
insula, cingulate, parieto-occipital and orbital/ventrolateral
prefrontal cortices in most studies of MDD and BD (e.g.,
Drevets et al. 1999, 2007; Sargent et al. 2000; Lopez et al.
1998), and the thermic and adrenocorticotropin/cortisol
responses to 5-HT1A receptor agonist challenge are blunted
in MDD (Lesch 1992). Conversely, chronic administration
of antidepressant drugs with diverse primary pharmaco-
logical actions enhances post-synaptic 5-HT1A receptor
function (Haddjeri et al. 1998; Chaput et al. 1991). Com-
patible with hypotheses that enhancement of 5-HT
transmission is relevant to maintaining remission in MDD,
about one-half of remitted MDD subjects who are
unmedicated or are being treated with SSRI agents expe-
rience depressive relapse under tryptophan depletion
(which putatively decreases central serotonergic function;
e.g., Neumeister et al. (2004).
It remains unclear whether the reduction in 5-HT1A
receptor function and expression in mood disorders con-
stitutes a neurodevelopmental or an acquired abnormality.
This issue is of interest because interruption of 5-HT1A
receptor function during neurodevelopment persistently
alters the function of emotion modulating systems in
genetically engineered mice (Gross et al. 2002). Never-
theless, the reduction in 5-HT1A receptor binding and
mRNA expression in depression may arise secondarily to
cortisol hypersecretion (Lopez et al. 1998), as the 5-HT1A
receptor mRNA expression and density are under tonic
inhibition by glucocorticoid receptor (GR) stimulation. In
experimental animals the increased CORT secretion during
chronic or repeated stress results in decreased 5-HT1A
receptor mRNA expression and density (Lopez et al. 1998;
Flugge 1995). Moreover, the mood and anxiety disordered
subgroups with reduced 5-HT1A receptor binding appear
limited to those who manifest evidence of a diathesis to
hypersecrete cortisol (e.g., under stressed conditions) (Lo-
pez et al. 1998; Drevets et al. 1999, 2007).
Altered serotonin transporter (5-HTT) function also is
thought to play a role in the pathophysiology of MDE
(Cannon et al. 2006b; Stockmeier 2003). Multiple genetic
polymorphisms involving 5-HTT regulatory sites report-
edly increase the vulnerability for developing mood
disorders (reviewed in Cannon et al. 2007). For example,
the common ‘‘short’’ allele of the functional 5-HTT LPR
polymorphism increases the vulnerability for developing
MDD within the context of stressful life events (Caspi
et al. 2003).
Catecholaminergic systems
The central dopaminergic and noradrenergic systems also
have been implicated in the pathophysiology of depression
and the mechanisms of antidepressant drugs (Nutt 2006).
Administration of reserpine or a-methyl-para-tyrosine,
which reduces the availability of brain catecholamines,
induces depressive syndromes in vulnerable individuals
(e.g., Hasler et al. 2008). Conversely, norepinephrine (NE)
reuptake inhibitors, dopamine (DA) reuptake inhibitors
(i.e., nomifensine) and dopamine receptor agonists (e.g.,
pramipexole) exert antidepressant effects in placebo-con-
trolled studies (Willner 1995; Zarate et al. 2004). In MDD
the CSF and jugular vein plasma levels of the DA metab-
olite, homovanillic acid, are abnormally decreased,
consistent with decreased DA turnover (Willner 1995;
Lambert et al. 2000). In contrast, the levels of NE metab-
olite concentrations were decreased in some (e.g., Lambert
et al. 2000), but increased in other studies (e.g., Veith et al.
1994). Neuroimaging studies of MDD showed reduced
striatal DA transporter binding and [
11C]L-DOPA uptake
across the blood–brain-barrier, consistent with reduced DA
neurotransmission (Nutt 2006). Finally, degeneration of
DA neurons in Parkinson’s Disease is associated with
increased vulnerability for developing a major depressive
syndrome (Santamaria et al. 1986).
The mesolimbic DA projections from the ventral teg-
mental area (VTA) to the nucleus accumbens shell and the
medial PFC play major roles in learning associations
between operant behaviors or sensory stimuli and reward,
and in mediating the reinforcing properties of drugs of
abuse and natural rewards such as food and sex (Nestler
and Carlezon 2006). Thus the evidence suggesting that DA
release is reduced in depression gave rise to hypotheses
that a reduction in mesolimbic DA function underlies the
anhedonia, amotivation and psychomotor slowing associ-
ated with MDE (Swerdlow and Koob 1987; Nestler and
Carlezon 2006). A preliminary study which used PET
measures of [C-11]raclopride binding to DA D2/D3
receptors to assess endogenous DA release found that
depressed subjects showed less DA release than healthy
controls in response to monetary reward (Martin-Soelch
and Drevets, unpublished data).
Cholinergic system
The cholinergic system is also implicated in the patho-
physiology of mood disorders, with evidence indicating
that the muscarinic cholinergic system is overactive or
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reported that increasing cholinergic activity using the ace-
tylcholine–esterase inhibitor physostigmine resulted in the
rapid induction of depressive symptoms in currently manic
bipolar subjects, and in a worsening of symptoms in uni-
polar depressed patients. In addition, depressed individuals
express exaggerated polysomnographic, neuroendocrine
and pupillary responses to cholinergic agonists or musca-
rinic receptor agonists relative to healthy controls (Dilsaver
1986; Janowsky et al. 1985; Janowsky and Overstreet 1995;
Rubin et al. 1999; Riemann et al. 1994), and aspects of
sleep abnormalities observed in depression, including
decreased REM latency and increased REM density (Gillin
et al. 1979), are thought to reﬂect hypersensitivity of
muscarinic cholinergic receptors. Taken together, these
data contribute to the hypothesis that a hyper-responsive
cholinergic system may contribute to mood symptoms
associated with mood disorders (Janowsky et al. 1994).
The preclinical literature also implicates the muscarinic
receptor system in mediating the cholinergic effects on
emotional behavior. In a line of rats genetically bred for
increased sensitivity of muscarinic receptors, the use
of cholinergic agonists results in the enhancement of
the behavioral analogs of depression, while the use of
antimuscarinic drugs results in the improvement in these
behaviors (Overstreet 1993). Consistently, the muscarinic
cholinergic receptor antagonist, scopolamine, exerts rapid
and robust antidepressant effects in depressed MDD and
BD patients (Furey and Drevets 2006).
Several studies more speciﬁcally implicate the M2-
receptor (M2R) in mood-regulation and depression. Mul-
tiple M2R gene polymorphisms were associated with
increased risk for developing MDE (Comings et al. 2002;
Wang et al. 2004). The administration of the M2R antag-
onist procaine elicits emotional responses in humans
ranging from sadness, fear and severe anxiety, to euphoria,
and results in increased physiological activity of the cin-
gulate cortex (Ketter et al. 1996; Benson et al. 2004), a
region densely innervated by cholinergic projections.
Finally, decreased M2R binding has been reported in the
cingulate cortex in bipolar depressives (Cannon et al.
2006a), using PET-neuroreceptor imaging (Fig. 4).
Cholinergic system dysfunction also may contribute to
the subjective sense of impaired concentration and mem-
ory, as well as the objective ﬁndings of attentional biases
in depression. Cholinergic neuromodulation inﬂuences
multiple cognitive processes, such that cholinergic
enhancement generally improves performance on memory
and attention tasks (Bartus et al. 1981; Peterson and
Gibson 1983) while blocking cholinergic activity impairs
Fig. 4 Reduced muscarinic
type 2 (M2) receptor binding in
the cingulate cortex in
depressed subjects with bipolar
disorder relative to healthy
controls. The statistical
parametric map shows voxel t
values corresponding to areas
where the uptake of [
18F]FP-
TZTP, a PET radioligand which
selectively binds M2 receptors,
was signiﬁcantly reduced (at
P\0.005) in bipolar
depressives relative to healthy
controls. The areas of maximal
difference between groups were
located in the anterior cingulate
cortex. Reproduced from
Cannon et al. (2006a)
Brain Struct Funct (2008) 213:93–118 105
123performance (Rusted and Warburton 1988; Sitaram et al.
1978). Acetylcholine is thought to act on neural processing
through signal-to-noise (S/N) mechanisms (Murphy and
Sillito 1991; Sato et al. 1987), and consistently researchers
have demonstrated that boosting cholinergic activity
increases the selectivity of neural response to target sen-
sory stimuli (Furey et al. 2000; Sillito and Kemp 1983;
Furey et al. 2007). In this way, the cholinergic inﬂuence on
S/N may represent the neural mechanism that underlies
the cholinergic inﬂuence on attention. Moreover, acetyl-
choline modulates emotional processing, both in animals
(McGaugh 2004; Power and McGaugh 2002) and in
humans (Bentley et al. 2003), and similarly may utilize
S/N modulation for differential representations of emo-
tional information.
Excessive cortical cholinergic activity in experimental
animals results in ‘‘hyperattentive impairments’’ (Sarter
et al. 2005), where over activity of the cholinergic system
reduces the signal detection threshold and leads to over
processing of stimuli. Given the central role of ACh in
emotional and sensory processing, the over-activity of the
cholinergic system in mood disorders conceivably could
alter S/N processing to produce an over-representation of
emotionally laden information, creating the emotional
processing bias and correlated cognitive deﬁcits (see
below).
Autonomic nervous system function in mood disorders
Relative to nondepressed controls matched for cardiac
disease, depressed patients show a two to fourfold increase
in sudden death and a sevenfold increase in ventricular
arrhythmia (Carney et al. 2005). This excess risk of cardiac
events in MDD is hypothesized to result partly from ele-
vated noradrenergic and sympathetic autonomic function,
coupled with reduced parasympathetic tone on the heart
rate (HR) (Carney et al. 2005).
Alterations of cognitive and emotional processing
in mood disorders
Cognitive and neuropsychological impairments are char-
acteristics of MDE, and are included in the diagnostic
criteria for MDD as ‘‘an impaired ability to think or con-
centrate’’ (APA 1994). Nonetheless, studies designed to
characterize cognitive symptoms in patients with mood
disorders have produced discrepant results. Some studies
have reported wide-ranging deﬁcits that include impair-
ments in early information processing, attention, memory,
and executive functions (Ottowitz et al. 2002; Tavares
et al. 2003), while other studies failed to identify such
deﬁcits (Channon et al. 1993; Grant et al. 2001; Purcell
et al. 1997). Several factors likely contribute to the
discrepancies in the literature, including heterogeneous
patient groups, medication status, and differences in cog-
nitive task paradigms that are presumed to assess the same
cognitive domain. Despite these discrepancies, a sufﬁcient
amount of evidence points consistently to the presence of
cognitive impairment in MDD and BD. Moreover, the
existence of residual cognitive deﬁcits in remitted patient
groups demonstrates that some cognitive features occur
independently of mood state (Clark et al. 2002; Tham et al.
1997).
Early information processing
Impairments in early information processing are evident in
patients with mood disorders. Inspection time, which is
measured as the minimum stimulus presentation time
necessary for near perfect performance on a two-choice
visual discrimination task, assesses the speed of early
information processing independent of motor speed or
cognitive strategy. Inspection time was reportedly longer in
unmedicated MDD patients than in medicated MDD or in
healthy controls (Tsourtos et al. 2002). In a visual back-
ward masking (VBM) task, where a stimulus is shown
brieﬂy and then ‘‘masked’’ or covered in space using a
noninformative stimulus, medicated BD subjects had deﬁ-
cits in the identiﬁcation of masked stimuli, consistent with
an impairment early in the information processing pathway
(Fleming and Green 1995).
Emotional processing bias
A consistently reported ﬁnding in mood disorders is a
mood-congruent processing bias, which is deﬁned as a
tendency to bias stimulus processing towards negative
information as compared to positive or neutral information
(Elliott et al. 2000; Murphy et al. 1999; Murray et al.
1999). In memory studies, currently depressed patients
have enhanced recall for negatively toned material as
compared to positively toned information (Bradley et al.
1995; Murray et al. 1999). In the context of attention
paradigms, depression-related negative words produce
more interference on emotional stroop tasks than do happy
or neutral words (Broomﬁeld et al. 2006; Gallardo Perez
et al. 1999). In an affective attention shifting task (i.e.,
affective go/no-go), medicated (Murphy et al. 1999) and
unmedicated (Erickson et al. 2005) depressed subjects are
faster when responding to the presentation of sad word as
compared to happy word targets, a ﬁnding that is consistent
with the idea that sad words are processed more readily. In
a face dot-probe task designed to assess the allocation of
attention between a face with a neutral expression and a
face with an emotional expression, individuals with MDD
consistently attend preferentially to faces with sad
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depressed patients are more negative in their interpretation
of ambiguous words (Mogg et al. 2006) and ambiguous
situations (Nunn et al. 1997) than are healthy participants.
Together, these ﬁndings suggest that a bias in stimulus
processing exists in patients with mood disorders that may
produce a preferential representation of negatively toned
information.
Functional neuroimaging studies have been used to
assess the relation between processing biases and func-
tional brain response in patients with mood disorders.
Results are consistent with behavioral ﬁndings, showing
altered neurophysiological responses in brain regions that
process emotional information (detailed above) during
tasks that utilize emotional stimuli. The amygdala shows
elevated levels of activity in MDD during exposure to sad
faces (Drevets et al. 2001), a ﬁnding that has been repli-
cated (Fu et al. 2004). Similarly, increased activity in
amygdala was observed during presentation of masked
fearful (Sheline et al. 2001) and masked sad faces (Fu et al.
2004) in MDD patients versus healthy controls, and higher
activity was seen in lateral orbital cortex following nega-
tive emotional stimuli in the affective go/no-go task (Elliott
et al. 2002). Similar increases in amygdala activity were
observed in response to sad faces in remitted subjects with
MDD (Neumeister et al. 2006a), suggesting that this
abnormality is trait-like in an MDD subgroup. In another
study, healthy volunteers showed a linear increase in
activity bilaterally in fusiform visual cortex and ventral
striatum as the intensity of a happy facial expression was
increased, while MDD patents showed a similar pattern of
increase in neural activity as the intensity of a sad
expression was increased, but the response pattern in the
patient group also extended into hippocampus and amyg-
dala (Surguladze et al. 2005). This literature suggests that
neural responses within the neural circuits underlying
emotional processing are altered, and that these altered
responses may represent the neurophysiological correlates
to the emotional processing bias observed in mood
disorders.
Attention, memory and learning
Subjective impairments of concentration and attention are
among the most commonly reported symptoms and sources
of functional impairment associated with MDE. Although
disagreement remains, standard measures of attention and
memory that depend on traditional neuropsychological test
batteries have failed to identify clear, consistent patterns of
deﬁcits in MDD and BD (Elliott et al. 1996; Grant et al.
2001; Purcell et al. 1997; Ravnkilde et al. 2002), and this
likely is due partially to the lack of tasks designed spe-
ciﬁcally for this clinical population. Selective attention
(without shifting set) and working memory (Landro et al.
2001; Rose and Ebmeier 2006; Stordal et al. 2004) have
been found to be impaired in depression, but these ﬁndings
have not been found consistently (Purcell et al. 1997), and
the results are complicated further by the fact that most
patients were medicated during study participation. Deﬁcits
in verbal memory have been identiﬁed in currently
depressed subjects and in unaffected twins and non-twin
siblings of BD subjects (Gourovitch et al. 1999; Keri et al.
2001; MacQueen et al. 2002), raising the possibility that
impaired verbal memory may constitute an endophenotype
for BD. Impairments of spatial recognition memory and
delayed matching to sample tasks also have been reported
in medicated subjects with MDD and BD (reviewed in
Taylor Tavares et al. 2007), but such impairments gener-
ally have not been reported in unmedicated samples with
MDD or BD (Grant et al. 2001; Purcell et al. 1997).
Implications for neurocircuitry models of depression
The neuropathological, neurophysiological and neuro-
chemical abnormalities extant within the extended
visceromotor network may impair this network’s modula-
tion of endocrine, autonomic, neurotransmitter, emotional
and behavioral responses to aversive and reward-related
stimuli or contexts (Ongu ¨r et al. 2003), potentially
accounting for the disturbances within these domains in
mood disorders (Fig. 5). The abnormally increased CBF
and metabolism in the orbital cortex, VLPFC, sgACC,
pgACC, amygdala, ventral striatum, and medial thalamus
evident in depression (Fig. 3) implicate a limbic-thalamo-
cortical circuit involving the amygdala, the mediodorsal
nucleus of the thalamus (MD) and the MPFC, and a limbic-
striatal-pallidal-thalamic circuit involving related parts of
the striatum and ventral pallidum along with the compo-
nents of the other circuit (Drevets et al. 1992). The ﬁrst of
these circuits can be conceptualized as an excitatory tri-
angular circuit (Fig. 5) whereby the BLA and the MPFC
are interconnected by excitatory (especially glutamatergic)
projections with each other and with the MD (Amaral and
Price 1984; Amaral and Insausti 1992; Bacon et al. 1996;
Kuroda and Price 1991; Jackson and Moghaddam 2001), so
increased glucose metabolism in these structures would
presumably reﬂect increased synaptic transmission through
the limbic-thalamo-cortical circuit. The limbic-striatal-
pallidal-thalamic circuit constitutes a disinhibitory side
loop between the amygdala or PFC and the MD. The
amygdala and the PFC send excitatory projections to
overlapping parts of the ventromedial striatum (Russchen
et al. 1985). This part of the striatum sends an inhibitory
projection to the ventral pallidum (Graybiel 1990) which in
turn sends GABA-ergic, inhibitory ﬁbers to the MD
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have relatively high spontaneous ﬁring rates (DeLong
1972), activity in the PFC or amygdala that activates the
striatum and in turn inhibits the ventral pallidum may
release the MD from the inhibitory pallidal inﬂuence,
potentially disinhibiting transmission through the limbic-
thalamo-cortical circuitry. Notably, repeated stress results
in hyperexcitability states in the BLA in rodents, although
whether the mechanisms underlying these changes involve
changes in afferent modulation of the amygdala or altera-
tions in synaptic plasticity have not been established
(Shekhar et al. 2005; Vyas et al. 2006).
The BLA sends anatomical projections to the central
nucleus of the amygdala (ACe) and the BNST, and
projections from these structures to the hypothalamus,
PAG, nucleus basalis, locus ceruleus, raphe and other
diencencephalic and brainstem nuclei play major roles in
organizing the neuroendocrine, neurotransmitter, autonomic,
and behavioral responses to stressors and emotional stimuli
(Davis and Shi 1999; LeDoux 2003). The MPFC sends
overlapping projections to each of these structures as well
as to the amygdala which function to modulate each
component of emotional expression (Ongu ¨r et al. 2003).
The neuropathological changes evident in the MPFC in
primary and some secondary mood disorders thus may
impair the modulatory role of the MPFC over emotional
expression, disinhibiting or dysregulating limbic responses
to stressors and emotional stimuli.
Reciprocal functional relationships between the cortical
(e.g., MPFC) and limbic (e.g., amygdala) structures that
modulate or mediate emotional expression have been
demonstrated by electrophysiological and lesion analysis
studies in experimental animals. In rats stimulation of
projections from the amygdala to the mPFC inhibits neu-
ronal ensemble activity in the mPFC, and stimulation of
projections from the mPFC to the amygdala excites
Fig. 5 Anatomical circuits involving the medial PFC (MPFC) and
amygdala reviewed within the context of a model in which MPFC
dysfunction results in disinhibition of limbic transmission through the
amygdala, yielding the emotional, cognitive, endocrine, autonomic
and neurochemical manifestations of depression. The basolateral
amygdala sends efferent projections to the central nucleus of the
amygdala (ACe) and the bed nucleus of the stria terminalis (BNST).
The efferent projections from these structures to the hypothalamus,
periaqueductal gray (PAG), nucleus basalis, locus ceruleus, raphe and
other diencencephalic and brainstem nuclei then organize the
neuroendocrine, neurotransmitter, autonomic, and behavioral
responses to stressors and emotional stimuli (Davis and Shi 1999;
LeDoux 2003). The MPFC shares reciprocal projections with all of
these structures (although only the connections with the amygdala are
illustrated) which function to modulate each component of emotional
expression (Ongu ¨r et al. 2003). Impaired MPFC function thus may
disinhibit or dysregulate limbic outﬂow through the ACe and BNST.
Solid white lines indicate some of the major anatomical connections
between structures, with closed arrowheads indicating the direction
of projecting axons. Solid yellow lines show efferent pathways of the
ACe and BNST, which generally are monosynaptic, but in some cases
are bisynaptic connections (e.g., Herman and Cullinan 1997). Other
abbreviations: 5-HT serotonin, ACh acetylcholine, DA dopamine, DL
dorsolateral column of PAG; N nucleus, NE norepinephrine, NTS
nucleus tractus solitarius, PVN paraventricular N of the hypothala-
mus, VL ventrolateral column of PAG, VTA ventral tegmental area.
Reproduced from Drevets (2007)
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123intra-amygdaloid GABA-ergic cells that inhibit neuronal
activity in the ACe (Likhtik et al. 2005; Perez-Jaranay and
Vives 1991). Moreover, rats exposed to fear-conditioned
stimuli show reduced mPFC neuronal ﬁring activity, and
the magnitude of this decrement correlates inversely with
the corresponding increase in amygdala neuron activity and
fear behavior (Garcia et al. 1999). Conversely, lesions of
the right or bilateral mPFC enhance behavioral, sympa-
thetic, and endocrine responses to stressors or fear-
conditioned stimuli in rats (Morgan and LeDoux 1995;
Sullivan and Gratton 1999).
Reciprocal relationships between the effects of MPFC
and amygdala function on emotional behavior also are
evident in humans. In MDD depression severity correlates
positively with amygdala and sgACC activity, but nega-
tively with activity in the left VLPFC/lateral orbital cortex
(Drevets et al. 2004). Lesions of the left orbital cortex
increase the risk for developing depression (MacFall et al.
2001), whereas electrical stimulation of the amygdala can
produce fear, anxiety, dysphoria, sympathetic autonomic
arousal, social withdrawal and cortisol release in humans
and/or nonhuman primates (reviewed in Drevets 2001).
Drugs and deep brain stimulation that exerts antidepressant
effects in MDD show a common effect of reducing phys-
iological activity in the amygdala and/or sgACC, despite
having diverse primary actions in the brain (Drevets et al.
2002a; Mayberg et al. 2005; Van Laere et al. 2006). In
contrast, a preliminary study found that interpersonal
psychotherapy, which also can reduce depressive symp-
toms in MDD, enhances activity in the VLPFC/anterior
insula (Brody et al. 2001a). Finally, higher activity in the
pgACC holds positive prognostic signiﬁcance in MDD, as
depressives who improve during antidepressant treatment
show higher pgACC metabolism and electrophysiological
activity than treatment-nonresponsive cases and healthy
controls (Mayberg et al. 1997; Pizzagalli et al. 2001).
Taken together, these data suggest that during depressive
episodes the increased activity seen within some MPFC
areas reﬂects a compensatory response which modulates
depressive symptoms, and impaired function of these
regions (possibly due to the neuropathological changes
described above) results in more severe and treatment-
refractory illness.
An impairment of MPFC function that disinhibits
amygdala activity also may contribute to the neuroendo-
crine, autonomic, neurotransmitter, attention and reward-
seeking abnormalities associated with MDE (Fig. 5). The
amygdala mediates the stressed component of glucocorti-
coid hormone secretion by disinhibiting CRF release from
the hypothalamic paraventricular nucleus (Herman and
Cullinan 1997). Conversely, the glucocorticoid response to
stress is inhibited by stimulation of glucocorticoid receptor
(GR) concentrations in the ventral ACC, such that
lesioning this cortex in rats increases ACTH and CORT
secretion during stress (Diorio et al. 1993). Excessive
amygdala activity combined with reduced ventral ACC
gray matter thus conceivably may contribute to the
excessive cortisol response to stress seen in depressed
humans (Drevets et al. 2002b; McEwen and Magarinos
2001; Gold et al. 2002).
The autonomic imbalance associated with depression
also could reﬂect MPFC dysfunction coupled with exces-
sive amygdala activity. Amygdala stimulation of the locus
ceruleus, lateral hypothalamus and PAG increases sympa-
thetic autonomic arousal in rodents (Fig. 5) (LeDoux 2003;
Gold and Chrousos 2002). In contrast the parasympathetic
tone on the heart-rate is partly regulated by projections
from the infralimbic cortex (which putatively forms the
posterior segment of the human sgACC) to the nucleus
tractus solitarius of the vagus nerve, and lesions of this
cortex reduce the parasympathetic tone on the heart in rats
(Frysztak and Neafsey 1994). The effects of increased
amygdala activity and reduced infralimbic cortex function
conceivably could account for the increased ratio of sym-
pathetic-to-parasympathetic tone on the heart rate seen in
depression (Carney et al. 2005).
Dysfunction of the MPFC coupled with amygdala
hyperactivity also may contribute to the anhedonia, amo-
tivation and inattention manifest in depression. The ACC
receives extensive dopaminergic innervation from the
VTA, and sends projections to the VTA that regulate
phasic DA release. In rats, stimulation of these ventral
ACC areas elicits burst ﬁring patterns in the VTA-DA
neurons, while inactivation of the ventral ACC converts
burst ﬁring patterns to pacemaker-like ﬁring activity
(Drevets et al. 1998; Murase et al. 1993; Taber and Fibiger
1993; Gariano and Groves 1988). The burst ﬁring patterns
increase DA release in the accumbens, which appears to
encode information regarding reward prediction in mon-
keys (Schultz et al. 1997). If the neuropathological changes
extant within the ventral ACC in mood disorders interfere
with its drive on VTA-DA neuronal burst ﬁring activity
they may impair reward perception, conceivably seen as a
loss of the pleasure and behavioral reinforcement derived
from normally rewarding activities.
In addition, the cognitive and behavioral response pat-
terns supporting goal- or reward-directed activity are
thought to depend upon PFC inputs to the ventral striatum,
which are maintained or ‘‘gated’’ by projections from the
hippocampal subiculum to the ventral striatum (Goto and
Grace 2005). Stimulation of projections from the amygdala
to the ventral striatum interrupts the maintenance of these
cortically driven response patterns, providing an adaptive,
limbic override that interrupts goal-directed thought or
behavior in response to unexpected threats or novelty.
Nevertheless, in MDE the excessive amygdala activity
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123conceivably could interfere with cognitive performance
and goal directed behavior to an extent that is maladaptive.
Antidepressant treatment effects
Considering the effects of antidepressant treatments on
circuitry-based models may elucidate common neuro-
physiological mechanisms that underlie their therapeutic
beneﬁts, despite the diversity of their primary actions in the
brain. For example, somatic antidepressant therapies of
various types modulate the activity in the amygdala,
potentially reducing the efferent transmission from the
central nucleus of the amygdala hypothesized to mediate
depressive symptoms in the model shown in Fig. 5.
Moreover, neurophysiological activity in the amygdala
decreases in rats, monkeys and/or humans during admin-
istration of treatments that show antidepressant efﬁcacy,
including drugs, vagal nerve stimulation or deep brain
stimulation of the anterior capsule (Drevets et al. 2002a;
Sheline et al. 2001; Fu et al. 2004; Van Laere et al. 2006;
Gerber et al. 1983; Henry et al. 1998). Notably in rats
(Horovitz 1966) observed that direct injection of antide-
pressant drugs (AD) into and speciﬁc lesions of the central
nucleus of the amygdala produced identical effects in
animal models used to predict AD efﬁcacy. In addition,
metabolism and ﬂow decrease in depressed humans in the
sgACC/ventromedial PFC in response to chronic treatment
with antidepressant drugs, vagus nerve stimulation or deep
brain stimulation of the sgACC or anterior capsule (May-
berg et al. 2005; Drevets et al. 2002a; Van Laere et al.
2006; Mayberg et al. 1999; Nahas et al. 2007; Conway
et al. 2006).
In considering broader networks, activity in the limbic-
thalamo-cortical circuitry decreases during effective treat-
ment (Drevets et al. 2002a; Drevets et al. 2004). The
cortical areas implicated include the orbital cortex, ven-
trolateral PFC, and/or anterior insula, where many studies
report that ﬂow or metabolism decrease during treatment
with antidepressant drugs or electroconvulsive therapy
(e.g., Brody et al. 2001b; Drevets 1992; Mayberg et al.
1999; Nobler et al. 1994). These areas show complex
relationships between depression severity and physiologi-
cal activity. While CBF and metabolism increase in these
areas in the depressed relative to the remitted phases of
MDD, the magnitude of these measures correlates inver-
sely with ratings of depression severity (Drevets et al.
1992). An inverse relationship between posterior orbital
cortex activity and the intensity of emotional experience
also is evident during anxiety provocation in subjects with
obsessive–complusive disorder and induced sadness in
healthy humans (Rauch et al. 1994; Schneider et al. 1995).
These data appear consistent with electrophysiological data
showing that parts of the orbital cortex participate in
modulating behavioral and visceral responses associated
with defensive, fear, and reward-directed behavior (Timms
1977; Rolls 1995), and that cerebrovascular lesions of the
frontal lobe (Starkstein and Robinson 1989) or more spe-
ciﬁcally the orbitofrontal cortex (MacFall et al. 2001)
increase the risk for developing major depression. Acti-
vation of the orbital cortex during depression thus may
reﬂect compensatory attempts to modulate emotional
expression or interrupt unreinforced aversive thought and
emotion. If so, then reducing CBF and metabolism in the
orbital cortex and ventrolateral PFC during antidepressant
drug treatment and electroconvulsive therapy may not
constitute a primary mechanism for ameliorating depres-
sive symptoms. Instead, direct inhibition of pathological
limbic activity in areas such as the amygdala and sgACC
may be more essential to correcting the pathophysiology
associated with mediating depressive symptoms, and the
reduction in orbital cortex/VLPFC activity may reﬂect a
secondary relaxation of these areas, once they are no longer
recruited to modulate pathological limbic activity.
Finally, preliminary reports observe that chronic SSRI
treatment or deep brain stimulation of the anterior capsule
additionally reduces the abnormally elevated metabolism in
the accumbens area in depression (Drevets et al. 2006)o ri n
depression associated with obsessive–complusive disorder
(Van Laere et al. 2006), and that deep brain stimulation
applied via electrodes situated in the accumbens area/ven-
tral internal capsule reportedly improves depressive
symptoms in treatment-refractory depression (Schlaepfer
et al. 2008). Taken together, these data suggest the impor-
tance of modulating activity within the limbic-striatal-
pallidal-thalamic circuitry in the treatment of depression.
Cognitive-behavioral strategies for managing depressive
symptoms may instead rely upon enhancing the function of
PFC systems that modulate limbic activity, thereby
enhancing the normal role of cortico-limbic circuits in
modulating emotional expression and experience (Siegle
et al. 2006). For example, interpersonal psychotherapy can
reduce depressive symptoms in MDD, and has been shown
to enhance activity in the VLPFC/anterior insula (Brody
et al. 2001a).
Summary
Convergent results from studies conducted using neuroim-
aging, lesion analysis and post mortem techniques support
models in which the signs and symptoms of depression
emanate from dysfunction within an extended visceromotor
network, which interferes with this system’s modulation of
emotional behavior. We have proposed more speciﬁcally
that the effects of impaired function in and between the
MPFC and related limbic structures can account for the
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123disturbances of emotional processing, cognitive perfor-
mance, neurotransmission, autonomic regulation and
neuroendocrine responses that are associated with mood
disorders.Somaticantidepressanttherapiesmaycompensate
for this dysfunction by modulating the pathological limbic
activity which putatively mediates depressive symptoms
(Drevets et al. 2002a) and the expression of neurotrophic/
neuroprotective factors that preserve the function of the
MPFC (Manji et al. 2001). Cognitive-behavioral strategies
for managing depressive symptoms may instead rely upon
enhancing the function of these MPFC systems, thereby
enhancing the normal role of cortico-limbic circuits in
modulating emotional processing and experience.
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